Baidu
map

Eur J Cancer:乳腺癌新辅助化疗添加钙调节药效果如何?

2016-01-18 Seven L 译 MedSci原创

先前有研究表明,绝经后乳腺癌患者辅助治疗时添加二膦酸盐可显著改善患者预后。研究者对4项前瞻性随机临床试验进行荟萃分析,比较II/III期乳腺癌患者新辅助化疗(CT)时候添加或不添加钙调节药唑来膦酸(ZA)的病理反应。以乳腺(pCRb)和淋巴结 (pCR)的病理完全缓解作为主要结局指标。此外研究者还对绝经后乳腺癌和三阴性乳腺癌进行了亚组分析。研究者获得了735名患者的pCRb数据,以及552名患者的

先前有研究表明,对绝经后乳腺癌患者辅助治疗时添加二膦酸盐可显著改善患者预后。研究者对4项前瞻性随机临床试验进行荟萃分析,比较II/III期乳腺癌患者新辅助化疗(CT)时添加或不添加钙调节药-唑来膦酸(ZA)的病理反应。以乳腺(pCRb)和淋巴结 (pCR)的病理完全缓解作为主要结局指标。此外研究者还对绝经后乳腺癌和三阴性乳腺癌进行了亚组分析。

研究者获得了735名患者的pCRb数据,以及552名患者的pCR数据。整个患者群体的研究表明,新辅助CT里添加ZA并不会增加整体pCRb或pCR的比例。不过对于绝经后乳腺癌患者,添加ZA可显著增加患者的pCRb率(CT vs CT+ZA:10.8% vs. 17.7%,OR 2.14, 95% CI  1.01-4.55),但不会增加患者pCR率(7.8%vs 14.6%, OR 2.62, 95% CI 0.90-7.62)。对三阴性乳腺癌的亚组分析提示CT+ZA组合更优的趋势。

该荟萃分析结果表明,新辅助化疗添加ZA不会对淋巴结指标产生益处,但是对绝经后乳腺癌患者CT+ZA组合还是会对患者大有裨益。

原始出处:

Kroep JR, Charehbili A,et al.Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.Eur J Cancer. 2015 Dec 23;54:57-63.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1678499, encodeId=d8d316e84996f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Mar 05 07:00:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814939, encodeId=275d1814939d4, content=<a href='/topic/show?id=8ee59638556' target=_blank style='color:#2F92EE;'>#钙调节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96385, encryptionId=8ee59638556, topicName=钙调节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Mar 29 17:00:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672289, encodeId=bbb216e22893b, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Nov 19 09:00:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86741, encodeId=a94986e41fa, content=非常有用,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/26EE52FB6741BE9C83BA4CC50B8BD4BF/100, createdBy=b50f1727200, createdName=草莓棉花糖7edb008f, createdTime=Sat May 21 10:12:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1678499, encodeId=d8d316e84996f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Mar 05 07:00:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814939, encodeId=275d1814939d4, content=<a href='/topic/show?id=8ee59638556' target=_blank style='color:#2F92EE;'>#钙调节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96385, encryptionId=8ee59638556, topicName=钙调节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Mar 29 17:00:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672289, encodeId=bbb216e22893b, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Nov 19 09:00:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86741, encodeId=a94986e41fa, content=非常有用,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/26EE52FB6741BE9C83BA4CC50B8BD4BF/100, createdBy=b50f1727200, createdName=草莓棉花糖7edb008f, createdTime=Sat May 21 10:12:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
    2016-03-29 saikp
  3. [GetPortalCommentsPageByObjectIdResponse(id=1678499, encodeId=d8d316e84996f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Mar 05 07:00:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814939, encodeId=275d1814939d4, content=<a href='/topic/show?id=8ee59638556' target=_blank style='color:#2F92EE;'>#钙调节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96385, encryptionId=8ee59638556, topicName=钙调节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Mar 29 17:00:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672289, encodeId=bbb216e22893b, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Nov 19 09:00:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86741, encodeId=a94986e41fa, content=非常有用,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/26EE52FB6741BE9C83BA4CC50B8BD4BF/100, createdBy=b50f1727200, createdName=草莓棉花糖7edb008f, createdTime=Sat May 21 10:12:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
    2016-11-19 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1678499, encodeId=d8d316e84996f, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Sat Mar 05 07:00:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814939, encodeId=275d1814939d4, content=<a href='/topic/show?id=8ee59638556' target=_blank style='color:#2F92EE;'>#钙调节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96385, encryptionId=8ee59638556, topicName=钙调节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Tue Mar 29 17:00:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672289, encodeId=bbb216e22893b, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat Nov 19 09:00:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86741, encodeId=a94986e41fa, content=非常有用,感谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/26EE52FB6741BE9C83BA4CC50B8BD4BF/100, createdBy=b50f1727200, createdName=草莓棉花糖7edb008f, createdTime=Sat May 21 10:12:00 CST 2016, time=2016-05-21, status=1, ipAttribution=)]
    2016-05-21 草莓棉花糖7edb008f

    非常有用,感谢!

    0

相关资讯

Cancer Res:中国科学家发现遏制乳腺癌进展的重要microRNA

许多研究表明转录因子NF-kB(nuclear factor kappa B)在肿瘤细胞中存在异常激活,是导致许多肿瘤发生的一个重要驱动因素。在正常的生理条件下,NF-kB信号的表达强度和持续时间会在多个水平上得到严格调控,但NF-kB信号途径在癌症中持续激活的机制究竟是什么一直没有得到完全阐述。 最近来自广州中山大学的研究人员在国际学术期刊cancer research上发表了一项最新研究进展

JNCI:乳腺癌风险评估工具BCRAT是否适用于≥75岁的老年女性

乳腺癌的风险评估工具 (BCRAT, "Gail model")现已广泛用于乳腺癌预测,BCRAT危险因素包括:年龄、种族/民族、初潮年龄、分娩年龄、家庭史、既往乳腺活检良性和异型性。但是该工具并没有在≥75岁女性中验证。因此研究组就该问题进行了一项研究。该研究共纳入73072名来自NHS和97081名来自WHI的女性参与者。NHS参与者中非西班牙籍白人更多,占96.2%,WHI中该数字为84.7

J Natl Cancer Inst:雌孕激素联合治疗会增加ER+乳腺癌的风险

先前有关于绝经后白人女性的观察性研究和随即试验表明,雌激素和孕激素联合治疗会导致雌激素受体阳性(ER+)乳腺癌风险增加。但是对于非裔美国女性是否同样存在该风险目前并不知道。因此研究者对1132例ER+和512例ER-的乳腺癌患者以及6693名对照参与者进行了一项研究,探究单独使用雌激素和联合治疗比较,对绝经后非裔美国女性ER+或ER-乳腺癌风险的影响。对照组中有57%的女性使用过单独雌激素或联合治

J Natl Cancer I:乳腺癌家族史和个人史人群MRI筛查比较

对有乳腺癌基因风险或家族史 (GFH)的人群推荐进行MRI筛查,但有乳腺癌个人史(PH)的人群是否进行MRI筛查目前证据仍不明确。因此研究者对乳腺癌家族史和个人史的人群进行了研究比较。研究者在纳入研究时和研究12个月时对参与者进行了MRI筛查,使用卡方检验识别年龄、既往MRI和MRI表现等之间的联系。采用Logistic回归预测多种变量对假阳性风险的综合作用。所有统计检验均为双侧。该研究共纳入了1

J Natl Cancer Inst:乳腺癌筛查——超声和钼靶比较

乳腺钼靶检查并没有在全世界范围内广泛应用,但当今乳腺癌发生率不断攀升却是事实。研究者进行了一项研究,拟探究超声对乳腺癌筛查的性能特点。该研究纳入了美国、加拿大、阿根廷等20个低点的2809名参与者,有2662名参与者完成了3年的超声筛查(共7473次检查)、屏幕式钼靶检查(n = 4351) 或数字化钼靶检查(n = 3122)和活检或者随访12个月。研究数据显示,110名女性共发生了111例乳腺

Cell:大规模乳腺癌功能基因组学研究结果发布,揭示肿瘤异质性,易感性和耐药机制

对乳腺癌细胞功能进行的一次迄今为止最大规模的分析调查,指出了数十个现有药物的新用途,一些药物发现新靶点及新的药物组合。作者们说,发布在1月14日《细胞》(Cell)杂志上的研究结果,可供全世界的实验室利用来鉴别其他类型癌症中的新候选药物及阐明癌细胞抵抗治疗的机制。在纽约大学Langone医学中心, Laura和Isaac Perlmutter癌症中心,及玛格丽特公主癌症中心研究人员的领导下,这一研

Baidu
map
Baidu
map
Baidu
map